A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Summary

This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days.

Timeline

Start

2016-11-25

Primary completion

2017-08-15

Completion

2017-08-15

Drugs

Indications

No indication recorded.